ABEO - Abeona Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ABEO is currently covered by 2 analysts with an average price target of $87.74. This is a potential upside of $82.33 (1521.81%) from yesterday's end of day stock price of $5.41.

Abeona Therapeutics's activity chart (see below) currently has 23 price targets and 34 ratings on display. The stock rating distribution of ABEO is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 38.19% with an average time for these price targets to be met of 161.58 days.

Highest price target for ABEO is $18, Lowest price target is $15, average price target is $87.74.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 25-Nov-2024. First documented stock forecast 06-Jan-2017.

Currently out of the existing stock ratings of ABEO, 9 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$9.74 (185.17%)

$15

2 months 3 days ago
(25-Nov-2024)

0/6 (0%)

$8.95 (147.93%)

Buy

$18

$12.74 (242.21%)

$18

2 months 30 days ago
(29-Oct-2024)

1/6 (16.67%)

$11.43 (173.97%)

61

Hold

$6

$0.74 (14.07%)

$5

2 years 2 months 14 days ago
(14-Nov-2022)

2/3 (66.67%)

$1.85 (44.58%)

257

Buy

$75

$70.79 (1681.47%)

$50

4 years 2 months 17 days ago
(11-Nov-2020)

2/3 (66.67%)

$45.92 (117.11%)

101

Buy

$22

4 years 8 months 20 days ago
(08-May-2020)

1/3 (33.33%)

$-59.25 (-72.92%)

820

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ABEO (Abeona Therapeutics) average time for price targets to be met?

On average it took 161.58 days on average for the stock forecasts to be realized with a an average price target met ratio 38.19

Which analyst has the current highest performing score on ABEO (Abeona Therapeutics) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on ABEO (Abeona Therapeutics)?

Jason Mccarthy works at MAXIM GROUP and has 2 price targets and 2 ratings on ABEO

Which analyst is the currently most bullish on ABEO (Abeona Therapeutics)?

Vernon Bernardino with highest potential upside - $720.79

Which analyst is the currently most reserved on ABEO (Abeona Therapeutics)?

Maury Raycroft with lowest potential downside - -$0

Abeona Therapeutics in the News

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

– PDUFA target action date is May 25, 2024 – – FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA – CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the...

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by late-November 2023 Initiated commercial readiness activities for potential U.S. launch of pz-cel CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE)...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?